SUMMARY: HIFU is used in the treatment of cancer (prostate, breast) and uterine fibroma but not yet in TNs. This case report describes the first successful ablation of a toxic TN with HIFU. TSH and radioiodine scan normalization were achieved without complications and maintained for 18 months. HIFU treatment is a minimally invasive technique that may be an effective safe alternative to radioiodine or surgery in patients with toxic TNs.
P
atients with AFTNs present with overt (toxic adenoma) or subclinical (pretoxic adenoma) hyperthyroidism. Standard definitive treatments are surgery or radioiodine.
1,2 Locally ablative methods, such as percutaneous intranodular ethanol injection, 3, 4 radio-frequency, 5 or laser ablation, 6, 7 have also been suggested as treatments. HIFU is a new minimally invasive technique that allows elective thermal tissue destruction (coagulative necrosis and cavitation) within a few seconds by focusing a beam onto a given target. 8 HIFU has been used in the treatment of prostate and breast cancer, as well as uterine fibroma. 9, 10 We previously reported our preliminary experience with HIFU in the ewe thyroid 11 and describe in the present case report the first successful ablation of an AFTN by using HIFU.
Case Report
A 26-year-old man presenting with muscle weakness and asthenia for 3 months was referred to our clinic for hyperthyroidism. The thyrotropin level was low (0.02 mIU/L, normal 0.1-4 mIU/L), but FT 4 and FT 3 levels were normal (16.86 and 4.5 pmol/L, respectively; normal, 10 -25 and 2.5-5.8 pmol/L, respectively). An 123 I thyroid scan revealed a hot right isthmolobar nodule with near-total suppression of extranodular iodine uptake and a low overall iodine uptake of 2% (Fig  1) . Daily iodine excretion was in the upper limit of normal values (155 g/24 hours). Symptomatic treatment with beta-blockers was initiated.
The patient was offered enrollment in a pilot monocentric noncomparative study analyzing the effectiveness and safety of an HIFU device (Theraclion, Paris Santé Cochin, France) in patients with AFTNs. The trial was designed to include patients with AFTN on scintigraphy who had TSH levels Յ0.1 mIU/L. After obtaining informed consent, we monitored clinical parameters and administered oral sedation. To prevent pain, we injected the nodule with 1% lidocaine under sonographic guidance. A specialist in ultrasonography performed the procedure under real-time sonographic guidance (Falcon; B-K Medical, Copenhagen, Denmark) by using a transducer (56-mm diameter; 38-mm focal length; 3-MHz frequency; focal region dimension, 2.5 ϫ 8 ϫ 1.8 mm). The nodule was spotted and drawn on the screen of a computer-controlled treatment unit (Thyros; Theraclion). This computer sequentially displaced the sonography beam over the nodule, creating multiple contiguous millimetric foci of necrosis. If the patient moved, treatment was automatically stopped. The HIFU session lasted 15 minutes (4 kJ delivered). Treatment was well tolerated. The patient subjectively assessed his pain as 25 on a visual analog scale of 0 -100. Neither blistering nor vocal cord palsy was observed. There was no clinical or biologic exac- erbation of hyperthyroidism. Two weeks after treatment, the nodule had become cystic. Biologic euthyroidism was achieved at 3 months (TSH, 1.91 mIU/L) and was maintained at 6, 12, and 18 months. At 12 and 18 months, the treated nodule was barely seen as a nonvascularized hypoechoic scar of 1.4 ϫ 1.6 mm. Thyroid scintigraphy showed a recovery of the thyroid iodine uptake (Fig 2) .
Discussion
Definitive treatment is always indicated in AFTNs with overt hyperthyroidism and is often recommended for patients with AFTNs and subclinical hyperthyroidism because of the risk of progression to overt hyperthyroidism. 1, 2 Radioiodine is a costeffective and safe procedure and the first choice of therapy for most patients with AFTNs. However, patients are somewhat reluctant to undergo this procedure in view of the policies and recommendations for reducing radiation hazards. Surgery may be preferred in young patients to avoid radiation exposure. The risks of surgery (vocal cord palsy, unavoidable scar, and general anesthesia) have to be taken into consideration.
Despite the small nodule size and normal FT 4 and FT 3 , the treatment decision for our patient was based on the clinical symptoms, nodule autonomy, TSH suppression, and the risk of future overt hyperthyroidism.
Radioiodine and surgery were both considered. The low iodine uptake, likely caused by transient iodine overload, did not favor radioiodine use. Surgery was not indicated because of the small size of the nodule and the patient's reservation toward surgery. Alternative treatments, such as ethanol injection, 3, 4 laser, 6, 12, 13 or radio-frequency ablation, 5 have been reported. Thyroid function is normalized after ethanol injection in approximately 60%-80% of pretoxic nodules and 35%-85% of toxic nodules. 3 Tarantino et al 4 reported complete cure (absent uptake in the nodule and recovery of normal uptake in the thyroid parenchyma) in 93% of patients with AFTNs. After laser ablation, cure rates of 61%-100% have been reported. 6, 13 Radio-frequency ablation has also been suggested as a potential nonsurgical therapeutic option. 5 These procedures are all minimally invasive, requiring, in the case of radio-frequency ablation, the insertion of electrodes into the thyroid nodule and at least 1.5-cm safety margins around the surrounding organs. 12 These treatments often require repeat injections or sessions to achieve total cure, especially in the case of large nodules. 12 Our procedure simply required local intranodular anesthetic, only 2-mm safety margins, and a single 15-minute HIFU session.
With only 1 case, it is too early to compare complication rates between HIFU and other techniques. A complication rate of 3.2%, including vocal cord palsy, abscess, and hematoma, was reported for percutaneous ethanol injection. 4 In our preliminary animal study, some injuries to neighboring organs, such as skin, trachea, esophagus, and recurrent nerves, were observed; however, the device we used in these studies was not fully suited for this purpose. 11 In other clinical applications of HIFU, skin burns and bowel infarction have been reported. 14, 15 Morbidity needs to be assessed on a larger scale. Due to stringent inclusion criteria regarding TSH, the tight deadlines of this pilot study, and the subsequent lack of participants, patient enrollment had to be stopped.
In conclusion, this is the first report of the cure of a small AFTN by using HIFU with excellent clinical, biologic, ultrasonographic, and scintigraphic results at 18 months. This case suggests the feasibility and effectiveness of a technique that is safely repeatable in patients with larger nodules. Although further evaluation is needed to confirm these results, this ambulatory, minimally invasive treatment seems to be a promising therapeutic alternative in clinical settings. Advantages over standard therapies would appear significant in terms of cost and morbidity. 
